Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies

Heart failure (HF) is a major public health priority due to its epidemiological transition and the world's aging population. HF is typified by continuous loss of contractile function with reduced, normal, or preserved ejection fraction, elevated vascular resistance, fluid and autonomic imbalanc...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutics and clinical risk management 2016-01, Vol.12 (Issue 1), p.887-906
Main Authors: Bonsu, Kwadwo Osei, Owusu, Isaac Kofi, Buabeng, Kwame Ohene, Reidpath, Daniel Diamond, Kadirvelu, Amudha
Format: Article
Language:English
Subjects:
Analysis
Cardiac function
Cardiomyocytes
Drug dosages
Drug therapy
Endoplasmic reticulum
Enzymes
experimental and clinical studies
Gene therapy
Health sciences
Heart failure
Homeostasis
Hypertension
Medical prognosis
Mortality
Novel treatment
Proteins
Review
therapeutic targets
Treatment outcome
Vectors (Biology)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart failure (HF) is a major public health priority due to its epidemiological transition and the world's aging population. HF is typified by continuous loss of contractile function with reduced, normal, or preserved ejection fraction, elevated vascular resistance, fluid and autonomic imbalance, and ventricular dilatation. Despite considerable advances in the treatment of HF over the past few decades, mortality remains substantial. Pharmacological treatments including β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists have been proven to prolong the survival of patients with HF. However, there are still instances where patients remain symptomatic, despite optimal use of existing therapeutic agents. This understanding that patients with chronic HF progress into advanced stages despite receiving optimal treatment has increased the quest for alternatives, exploring the roles of additional pathways that contribute to the development and progression of HF. Several pharmacological targets associated with pathogenesis of HF have been identified and novel therapies have emerged. In this work, we review recent evidence from proposed mechanisms to the outcomes of experimental and clinical studies of the novel pharmacological agents that have emerged for the treatment of HF.
ISSN:1176-6336
1178-203X
1178-203X
DOI:10.2147/TCRM.S106065